First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

Lung

Volumn 194, Issue 5, 2016, Pages 739-743

  Wuyts, Wim A ^a   Kolb, Martin ^b   Stowasser, Susanne ^c   Stansen, Wibke ^c   Huggins, John T ^d   Raghu, Ganesh ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MCMASTER UNIVERSITY   (Canada)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Clinical trial; Disease progression; Interstitial lung diseases; Tyrosine kinase

Indexed keywords

NINTEDANIB; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE;

AGED; ARTICLE; BRONCHITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; VITAL CAPACITY;

AGED; DIARRHEA; DISEASE PROGRESSION; DYSPNEA; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; VITAL CAPACITY;

EID: 84976870330     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-016-9912-1     Document Type: Article

References (17)

1. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824
2. du Bois RM, Nathan SD, Richeldi L et al (2012) Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 186:712–715
3. Karimi-Shah BA, Chowdhury BA (2015) Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med 372:1189–1191
4. Hilberg F, Roth GJ, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782
5. Wollin L, Wex E, Pautsch A et al (2015) Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45:1434–1445
6. Boehringer Ingelheim Pharmaceuticals, Inc. (2016) OFEV™ (nintedanib) prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf. Accessed 25 May 2016
7. Boehringer Ingelheim (2016) OFEV (nintedanib) Summary of Product Characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf. Accessed 17 March 2016
8. Raghu G, Rochwerg B, Zhang Y et al (2015) An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192:e3–e19
9. Richeldi L, du Bois RM, Raghu G et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082
10. Noble PW, Albera C, Bradford WZ et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:1760–1769
11. Richeldi L, Costabel U, Selman M et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087
12. King TE Jr, Bradford WZ, Castro-Bernardini S et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092
13. Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA et al (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:2093–2101
14. Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 24:420–427
15. ®. Am J Respir Crit Care Med 193:178–185
16. Maher TM, Flaherty KR, Noble PW et al (2015) Effect of baseline FVC on lung function decline with nintedanib in patients with IPF. Eur Respir J 46(Suppl 59):OA4499
17. ® trials. Am J Respir Crit Care Med 191:A1021